NVILE forecast ·

Johnson & Johnson (JNJ) Stock Forecast: Next 30 Days

Over the next 30 days, JNJ has an 80% calibrated price range of $255.18 to $296.20, starting from $273.20. Calibrated distribution estimates show a 4% probability of dropping more than 10% and a 7% probability of gaining more than 10%. Price history alone exhibits no tested 30-day directional edge, and the expected middle value of $274.93 is not a price target. Wall Street views remain mixed, with 12-month targets averaging $279.41 to $289.71 against near-term downward EPS revisions.

Price now

$273.20

Oct 30, 2026

In 30 days

$274.93

NVILE forecast

Expected move

+0.6%

Range

$255.18–$296.20

$295.54$270.54$245.54Jun 25, 2026Today+30d

What to do

  • Structure conditional range-bound exposure rather than directional bets over the 30-day horizon.The statistical model highlights a balanced 80% range between $255.18 and $296.20 with modest tail probabilities.
  • Monitor upcoming earnings adjustments and executive filing disclosures for fundamental validation.[2],[8]Recent insider transactions totaling $61.99M in sales and downward EPS revisions warrant conservative position sizing.

Why

  • JNJ's calibrated 30-day 80% range spans $255.18 to $296.20, with a 4% chance of falling over 10% and a 7% chance of rising over 10%.
  • Consensus 12-month price targets average $279.41, with analyst targets ranging widely from $190.00 to $320.00.[8],[10],[12]
  • Current-quarter EPS estimates were revised down 1.8% over the past 30 days, with 2 downward revisions and 0 upward revisions.[8]
  • JNJ stock gained 42% over the trailing year as talc litigation settlements progressed and newer pharmaceutical therapies compensated for Stelara revenue declines.[9]
  • Executive leadership executed open-market sales totaling $61.99M across 9 transactions over 90 days, including sales by CEO Joaquin Duato.[2]

What could go wrong

  • Active shareholder litigation and legal investigations, such as Pomerantz LLP's inquiry into disclosure issues, create headline volatility.[11]
  • Continued negative earnings revisions may compress valuation multiples if pharmaceutical product rotation fails to offset patent expiries.[8],[9]

How it connects

  • Joaquin Duatoserves as Director, CEO, and Chairman of the Board ofJohnson & Johnson[2]
  • Joaquin Duatosold 165,248 shares across multiple open-market transactionsJohnson & Johnson[2]
  • Timothy Schmidserves as EVP, WW Chair, MedTech atJohnson & Johnson[2]
  • Timothy Schmidsold 22,527 shares at $274.74Johnson & Johnson[2]
  • Johnson & Johnsonheld approximately 89.6% of common stock post-IPOKenvue[3]
  • Johnson & Johnsonmanufactures and distributes pharmaceutical therapyStelara[9]
  • Michael Yeepublishes equity research as an analyst forUBS[10]
  • UBSmaintained Buy rating with a $320 price target onJohnson & Johnson[10]
  • Pomerantz LLPinvestigates investor claims againstJohnson & Johnson[11]
  • S&P Globalpolled 23 analysts yielding an average $279.41 price target forJohnson & Johnson[12]

NVILE's track record on this page

MadeForecastActualResult
Nov 2, 2026$274.93Due Dec 2, 2026Pending
Oct 30, 2026$276.94Due Nov 29, 2026Pending

Every published call is scored when it comes due. See all results →

Sources

  1. 1.JNJ daily short-sale volume (FINRA) · finra.org
  2. 2.JOHNSON & JOHNSON insider transactions (SEC Form 4) · sec.gov
  3. 3.JOHNSON & JOHNSON 10-K (2026-02-11) · sec.gov
  4. 4.JNJ | Johnson & Johnson Stock Overview (U.S.: NYSE) | Barron's · barrons.com
  5. 5.Johnson & Johnson has a chance to show it's more than just a rotation winner · cnbc.com
  6. 6.JNJ | Johnson & Johnson Analyst Estimates & Ratings - WSJ · wsj.com
  7. 7.JNJ: Johnson & Johnson Stock Price Quote - New York - Bloomberg · bloomberg.com
  8. 8.JNJ Wall Street consensus: estimates, revisions, ratings, targets · finance.yahoo.com
  9. 9.Johnson & Johnson Is Up 42% in a Year: Take Profits, or Buy More? · finance.yahoo.com
  10. 10.Analysts Offer Insights on Healthcare Companies: Johnson ... · theglobeandmail.com
  11. 11.INVESTOR ALERT: Pomerantz Law Firm Investigates ... · globenewswire.com
  12. 12.Johnson & Johnson (JNJ) Stock Forecast & Analyst Price ... · stockanalysis.com

Questions

What is the Johnson & Johnson forecast for the next 30 days?

NVILE's models put Johnson & Johnson at about $274.93 in 30 days, +0.6% from $273.20. Over the next 30 days, JNJ has an 80% calibrated price range of $255.18 to $296.20, starting from $273.20. Calibrated distribution estimates show a 4% probability of dropping more than 10% and a 7% probability of gaining more than 10%. Price history alone exhibits no tested 30-day directional edge, and the expected middle value of $274.93 is not a price target. Wall Street views remain mixed, with 12-month targets averaging $279.41 to $289.71 against near-term downward EPS revisions.

What price range does NVILE expect for Johnson & Johnson?

The forecast range is $255.18 to $296.20 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.

What could change the Johnson & Johnson outlook?

Active shareholder litigation and legal investigations, such as Pomerantz LLP's inquiry into disclosure issues, create headline volatility. Continued negative earnings revisions may compress valuation multiples if pharmaceutical product rotation fails to offset patent expiries.

What should investors watch or do about Johnson & Johnson?

Structure conditional range-bound exposure rather than directional bets over the 30-day horizon. Monitor upcoming earnings adjustments and executive filing disclosures for fundamental validation.

How accurate are NVILE forecasts?

Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.

This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.